Nouscom AG
- Biotech or pharma, therapeutic R&D
Nouscom is a private clinical stage immuno-oncology company developing next-generation, off-the-shelf and personalized cancer immunotherapies. Our technology and programs include:
- Technology platform: Our proprietary viral vector platform has the capacity to encode for large payloads of neoantigens or other immunomodulators and is clinically demonstrated to safely and potently harness the power of the immune system.
- NOUS-209: off-the-shelf immunotherapy being developed for cancer interception in high-risk Lynch syndrome carriers as well as for the treatment of MSI-H solid tumors
- NOUS-PEV: personalized cancer immunotherapy for the treatment of a broad range of cancers that will be entering randomized Phase 2 trials in 2026.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}